Corporate | 13 April 2007 08:01
WILEX AG / Quarter Results
Release of a Corporate-announcement, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
WILEX publishes Q1 2007 figures – results in line with expectations
Munich, 13 April 2007. The Munich-based biopharmaceutical company WILEX AG
(ISIN DE0006614720/Frankfurt Stock Exchange/Prime Standard) today published
its results and report for the first quarter of 2007 (1 December 2006 – 28
February 2007). The results are in line with the Company's expectations.
- Operating expenses in the first quarter of 2007 totalled EUR 5.9 million
(Q1 2006: EUR 3.2 million; an increase of 81.0%). This was largely due to
the increase in research and development costs from EUR 2.5 million in the
first quarter of the previous year to EUR 4.9 million in Q1 2007 and is
primarily attributable to the progress realised in the Phase III ARISER
trial with a growing number of patients and trial centres. Research and
development costs as a percentage of total expenditure increased from 78.4
% in Q1 2006 to 83.6 % in Q1 2007.
- Other operating income totalled EUR 0.51 million in Q1 2007, up from EUR
0.15 million in the same period of the previous year (increase of 237.9%).
- In line with expectations, WILEX closed Q1 2007 with earnings before tax
of EUR -4.9 million (previous year: EUR -4.1 million; increase of 20.5%).
The Company progressed the development of its portfolio of drugs and
medical products in the first quarter of 2007. The key events were:
- Patient recruitment in the Phase III ARISER trial is outstanding. As
announced recently, more than 420 of the 856 patients, whose data are
required for the approval applications in Europe and the USA, were enrolled
in the trial.
- WILEX signed a manufacturing and distribution agreement with IBA
Molecular N.A., Sterling, USA. IBA will radioactively label the WILEX
antibody and supply it to the participating trial centres in the imminent
registration trial for the imaging diagnostic agent CA9-SCAN.
- WILEX received approval from the Federal Institute for Drugs and Medical
Devices (BfArM) to conduct a clinical Phase II trial with WX-671 in
patients with advanced, inoperable and non-metastatic pancreatic cancer.
This represents an important milestone in the development of our
anti-metastatic uPA inhibitors. Patient recruitment is expected to start in
the second quarter.
'Our projects are progressing in line with expectations,' commented Peter
Llewellyn-Davies, CFO of WILEX AG. 'We expect the futility analysis of our
Phase III ARISER trial to become available in the second half of 2007. This
should provide an indication of whether the trial is likely to produce a
positive result. Subsequently, we will focus on the commercialisation of
our portfolio.'
The quarterly report was published on the Company's website: www.wilex.com.
This communication contains certain forward-looking statements, relating to
the Company’s business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
Given these uncertainties, prospective investors and partners are cautioned
not to place undue reliance on such forward-looking statements. We disclaim
any obligation to update any such forward-looking statements to reflect
future events or developments.
Juliane Giese
Manager Public Relations
Tel.: +49 (0)89-41 31 38-29
Email: investors@WILEX.com
DGAP 13.04.2007
----------------------------------------------------------------------
Language: English
Issuer: WILEX AG
Grillparzerstr. 16
81675 München Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
www: www.wilex.de
ISIN: DE0006614720
WKN: 661472
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------